Exclusive Archives

Exclusive By Rachel Cohrs

White House’s Jen Psaki offered a binder full of Covid spending details. Taking a peek was a process

Exclusive By Ed Silverman

Justice Department probes Bausch Health over marketing for dermatology drugs

Exclusive By Nicholas Florko

Warren, Grassley threaten to slap FDA with a 30-day deadline for OTC hearing aid rules

Exclusive By Matthew Herper

Douglas Melton, noted stem cell researcher, leaves Harvard for Vertex to create diabetes treatments

Exclusive By Lev Facher

Key lawmaker: ARPA-H won’t be part of NIH

Exclusive By Nicholas Florko and Rachel Cohrs

More Democrats flag ‘questions,’ remain uncertain about Biden’s FDA pick, Robert Califf

Exclusive By Casey Ross

He founded what became IBM’s most valuable health database. Now, he’s sounding an alarm about patient privacy

Exclusive By Rachel Cohrs

The Biden administration used billions in hospital Covid-19 funds to pay drugmakers

Exclusive By Damian Garde and Adam Feuerstein

With its Alzheimer’s drug in turmoil, Biogen eyes a list of potential acquisitions

Exclusive By Eric Boodman

A tiny Florida company got more of a scarce Covid therapy than some big hospitals, raising equity questions

Exclusive By Adam Feuerstein and Damian Garde

Moderna, Amgen among biotech heavyweights pulling out of JPM conference over Covid concerns

Exclusive By Katie Palmer

‘A multi-decade journey’: Chan Zuckerberg Initiative invests another $3.4 billion to advance scientific tools

Exclusive By Kate Sheridan

Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s

Exclusive By Rachel Cohrs

How Nancy Pelosi almost killed drug pricing reform — a gamble that expanded Democrats’ final deal

Exclusive By Katie Palmer

Alphabet has a new drug discovery company building on DeepMind’s AI chops

Exclusive By Rachel Cohrs and Nicholas Florko

Key Senate committee considers a carveout for small biotech companies in drug pricing reforms

Exclusive By Adam Feuerstein and Damian Garde

Biogen’s Aduhelm sales slower than disclosed, forcing company to consider cost-cutting measures

Exclusive By Rachel Cohrs

Senate proposes expanding pharma penalties for hiking drug prices

Exclusive By Nicholas Florko and Rachel Cohrs

Senate considers pegging Medicare drug prices to deeply discounted Veterans Affairs rates

Exclusive By Erin Brodwin

Cityblock Health raises another mega-round of funding, tipping its valuation over $5 billion

Exclusive By Nicholas Florko

‘Change is messy’: Inside the tumultuous efforts to stabilize BIO, the biotech lobby

Exclusive By Olivia Goldhill

Inside Pfizer’s labs, ‘variant hunters’ race to stay ahead of the pandemic’s next twist

Exclusive By Kate Sheridan

Flagship, Orbimed, ARCH, Alta top list of high-performing biotech venture capital firms

Exclusive By Damian Garde

Sesen Bio trial of cancer drug marked by misconduct and worrisome side effects, documents show

Exclusive By Megan Molteni

Most Read

NIH’s cancer chief, Ned Sharpless, to step down

Biden’s high-stakes biomedical science agency ARPA-H will be part of the NIH — but there’s a twist

Lawmakers and a Pelosi aide turn lobbyist to push for new health agency’s independence

New details emerge about a U.S. scientist’s obscured role in the ‘CRISPR babies’ scandal

Inside the culture of fear in Eric Lander’s White House science office

The Catholic hospital system Ascension is running a Wall Street-style private equity fund

Inside ‘Project Onyx’: How Biogen used an FDA back channel to win approval of its polarizing Alzheimer’s drug

The Trump administration quietly spent billions in hospital funds on Operation Warp Speed

All Coverage

White House’s Jen Psaki offered a binder full of Covid spending details. Taking a peek was a process

Justice Department probes Bausch Health over marketing for dermatology drugs

Warren, Grassley threaten to slap FDA with a 30-day deadline for OTC hearing aid rules

Douglas Melton, noted stem cell researcher, leaves Harvard for Vertex to create diabetes treatments

Key lawmaker: ARPA-H won’t be part of NIH

More Democrats flag ‘questions,’ remain uncertain about Biden’s FDA pick, Robert Califf

He founded what became IBM’s most valuable health database. Now, he’s sounding an alarm about patient privacy

The Biden administration used billions in hospital Covid-19 funds to pay drugmakers

With its Alzheimer’s drug in turmoil, Biogen eyes a list of potential acquisitions

A tiny Florida company got more of a scarce Covid therapy than some big hospitals, raising equity questions

Moderna, Amgen among biotech heavyweights pulling out of JPM conference over Covid concerns

‘A multi-decade journey’: Chan Zuckerberg Initiative invests another $3.4 billion to advance scientific tools

Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s

How Nancy Pelosi almost killed drug pricing reform — a gamble that expanded Democrats’ final deal

Alphabet has a new drug discovery company building on DeepMind’s AI chops

Key Senate committee considers a carveout for small biotech companies in drug pricing reforms

Biogen’s Aduhelm sales slower than disclosed, forcing company to consider cost-cutting measures

Senate proposes expanding pharma penalties for hiking drug prices

Senate considers pegging Medicare drug prices to deeply discounted Veterans Affairs rates

Cityblock Health raises another mega-round of funding, tipping its valuation over $5 billion

‘Change is messy’: Inside the tumultuous efforts to stabilize BIO, the biotech lobby

Inside Pfizer’s labs, ‘variant hunters’ race to stay ahead of the pandemic’s next twist

Flagship, Orbimed, ARCH, Alta top list of high-performing biotech venture capital firms

Sesen Bio trial of cancer drug marked by misconduct and worrisome side effects, documents show

Anti-aging foundation’s CEO left amid an investigation of co-founder Aubrey de Grey